Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L.

Food and Chemical Toxicology

Volumn 60, Issue , 2013, Pages 98-108

  Koe, Xue Fen ^a   Lim, Ee Lin ^a   Seah, Tiong Chai ^a   Amanah, Azimah ^a   Wahab, Habibah Abdul ^a,b   Adenan, Mohd Ilham ^a,c   Sulaiman, Shaida Fariza ^b   Tan, Mei Lan ^a,d  

^a Kemeneterian Sains Teknologi dan Inovasi   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c FOREST RESEARCH INSTITUTE MALAYSIA   (Malaysia)

^d ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

Author keywords

CYP3A4; Cytochrome P450 induction assay; Cytochrome P450 inhibition assay; Deoxyelephantopin; Drug herb interactions

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEOXYELEPHANTOPIN; MESSENGER RNA; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELEPHANTOPUS SCABER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION;

CYP3A4; CYTOCHROME P450 INDUCTION ASSAY; CYTOCHROME P450 INHIBITION ASSAY; DEOXYELEPHANTOPIN; DRUG-HERB INTERACTIONS;

ASTERACEAE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; GREEN FLUORESCENT PROTEINS; HEP G2 CELLS; HUMANS; LACTONES; PROMOTER REGIONS, GENETIC; PROTEIN CONFORMATION; RNA, MESSENGER; SESQUITERPENES;

EID: 84881538681     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.07.030     Document Type: Article

References (37)

1. Bowen W.P., Carey J.E., Miah A., McMurray H.F., Munday P.W., James R.S., Coleman R.A., Brown A.M. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2000, 28:781-788.
2. Brandon E.F., Raap C.D., Meijerman I., Beijnen J.H., Schellens J.H. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacool. 2003, 189:233-246.
3. But P.P.H., Hon P.M., Cao H., Chan T.W.D., Wu B.M., Mak T.C.W., Che C.T. Sesquiterpene lactones from Elephantopus scaber. Phytochemistry 1997, 44:113-116.
4. Cardoza R.M., Amin P.D. A stability indicating LC method for felodipine. J. Pharm. Biomed. Anal. 2002, 27:711-718.
5. Daisy P., Jasmine R., Ignacimuthu S., Murugan E. A novel steroid from Elephantopus scaber L. an ethnomedicinal plant with antidiabetic activity. Phytomedicine: Int. J. Phytother. Phytopharmacol. 2009, 16:252-257.
6. Dixit V., Hariparsad N., Desai P., Unadkat J.D. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm. Drug Dispos. 2007, 28:257-262.
7. Ekroos M., Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA 2006, 103:13682-13687.
8. Fahmi O.A., Kish M., Boldt S., Obach R.S. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab. Dispos. 2010, 38:1605-1611.
9. FDA, 2006. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
10. FDA, 2012. Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
11. Galetin A., Clarke S.E., Houston J.B. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 2002, 30:1512-1522.
12. Geetha B.S., Nair M.S., Latha P.G., Remani P. Sesquiterpene lactones isolated from Elephantopus scaber L. inhibits human lymphocyte proliferation and the growth of tumour cell lines and induces apoptosis in vitro. J. Biomed. Biotechnol. 2012, 2012:721285.
13. Gibbs M.A., Hosea N.A. Factors affecting the clinical development of cytochrome p450 3A substrates. Clin. Pharmacokinet. 2003, 42:969-984.
14. Hammer M.L., Johns E.A. Tapping an amazonian plethora: four medicinal plants of Marajo Island, Para (Brazil). J. Ethnopharmacol. 1993, 40:53-75.
15. Ho, W.Y., Yeap, S.K., Ho, C.L., Abdul Rahim, R., Alitheen, N.B., 2012. Hepatoprotective activity of elephantopus scaber on alcohol-induced liver damage in mice. Evidence-based complementary and alternative medicine: eCAM 2012, 417953.
16. Huang C.C., Lo C.P., Chiu C.Y., Shyur L.F. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice. Br. J. Pharmacol. 2010, 159:856-871.
17. Kenworthy K.E., Bloomer J.C., Clarke S.E., Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 1999, 48:716-727.
18. Lee H.W., Kim D.W., Phapale P.B., Lim M.S., Park J., Seo J.J., Park K.M., Park Y.K., Yoon Y.R. In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms. J. Clin. Pharm. Ther. 2011, 36:496-503.
19. Lee W.L., Wen T.N., Shiau J.Y., Shyur L.F. Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells. J. Proteome Res. 2010, 9:237-253.
20. Li A.P., Maurel P., Gomez-Lechon M.J., Cheng L.C., Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. 1997, 107:5-16.
21. Liang Q.L., Min Z.D., Tang Y.P. A new elemanolide sesquiterpene lactone from Elephantopus scaber. J. Asian Nat. Prod. Res. 2008, 10:403-407.
22. Lim E.L., Seah T.C., Koe X.F., Wahab H.A., Adenan M.I., Jamil M.F., Majid M.I., Tan M.L. In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid. Toxicol In. Vitro 2013, 27:812-824.
23. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., Chavin K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003, 290:1500-1504.
24. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
25. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
26. Obach R.S., Walsky R.L., Venkatakrishnan K., Houston J.B., Tremaine L.M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther. 2005, 78:582-592.
27. Pan Y., Abd-Rashid B.A., Ismail Z., Ismail R., Mak J.W., Pook P.C., Er H.M., Ong C.E. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J. Ethnopharmacol. 2010, 130:275-283.
28. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Maurel P., Vilarem M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003, 1619:243-253.
29. Patki K.C., Von Moltke L.L., Greenblatt D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. 2003, 31:938-944.
30. Rendic S., Guengerich F.P. Update information on drug metabolism systems-2009, Part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr. Drug Metab. 2010, 11:4-84.
31. Rodeiro I., Donato M.T., Lahoz A., Garrido G., Delgado R., Gomez-Lechon M.J. Interactions of polyphenols with the P450 system: possible implications on human therapeutics. Mini. Rev. Med. Chem. 2008, 8:97-106.
32. Sevrioukova I.F., Poulos T.L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc. Natl. Acad. Sci. USA 2010, 107:18422-18427.
33. Su M., Chung H.Y., Li Y. Deoxyelephantopin from Elephantopus scaber L. induces cell-cycle arrest and apoptosis in the human nasopharyngeal cancer CNE cells. Biochem. Biophys. Res. Commun. 2011, 411:342-347.
34. Walsky R.L., Boldt S.E. In vitro cytochrome P450 inhibition and induction. Curr. Drug Metab. 2008, 9:928-939.
35. Wienkers L.C. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J. Pharmacol. Toxicol. Methods 2001, 45:79-84.
36. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 2000, 32:339-361.
37. Yan Z., Caldwell G.W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 2001, 1:403-425.